

# Effective GH Replacement with Somapacitan in Children with GH Deficiency: REAL4 2-year Results after Switch from Daily GH

Bradley S. Miller, Joanne C. Blair, Michael Højby Rasmussen, Aristides Maniatis, Jun Mori, Volker Böttcher, Ho-Seong Kim, Rikke Beck Bang, Michel Polak, and Reiko Horikawa


J Clin Endocrinol Metab. 2023. Doi: 10.1210/clinem/dgad394

## Background


- **Somapacitan** is a long-acting human growth hormone (GH) analogue injected subcutaneously **once a week**
- Previous clinical trial results have shown **similar efficacy and safety** of weekly somapacitan (0.16 mg/kg/week) **compared to daily GH** (0.034 mg/kg/day) in children with GH deficiency (GHD)

## Aim

To evaluate **efficacy, safety and patient preferences** after **two years** of once-weekly somapacitan treatment and after one year of once-weekly somapacitan following the switch from daily GH in children with GHD, as part of the REAL4 clinical trial



## Key findings



After 2 years, the children in both treatment groups had **grown to a similar extent** (comparable height velocity and height standard deviation score)

According to a questionnaire given to caregivers of the children who switched from taking daily GH to weekly somapacitan for the second year, **almost all (45/50) preferred somapacitan**, while no one preferred daily GH



The **side effects** among the children in both study groups **were mild** and mostly events that are common in children, such as the common cold and fever

## Conclusions

These findings show that **two years of treatment with weekly somapacitan is effective and well-tolerated in children with GHD, and is the preferred treatment option over daily GH**